Oligonucleotide conjugated antibody strategies for cyclic immunostaining

Sci Rep. 2021 Dec 13;11(1):23844. doi: 10.1038/s41598-021-03135-9.

Abstract

A number of highly multiplexed immunostaining and imaging methods have advanced spatial proteomics of cancer for improved treatment strategies. While a variety of methods have been developed, the most widely used methods are limited by harmful signal removal techniques, difficulties with reagent production and antigen sensitivity. Multiplexed immunostaining employing oligonucleotide (oligos)-barcoded antibodies is an alternative approach that is growing in popularity. However, challenges remain in consistent conjugation of oligos to antibodies with maintained antigenicity as well as non-destructive, robust and cost-effective signal removal methods. Herein, a variety of oligo conjugation and signal removal methods were evaluated in the development of a robust oligo conjugated antibody cyclic immunofluorescence (Ab-oligo cyCIF) methodology. Both non- and site-specific conjugation strategies were assessed to label antibodies, where site-specific conjugation resulted in higher retained binding affinity and antigen-specific staining. A variety of fluorescence signal removal methods were also evaluated, where incorporation of a photocleavable link (PCL) resulted in full fluorescence signal removal with minimal tissue disruption. In summary, this work resulted in an optimized Ab-oligo cyCIF platform capable of generating high dimensional images to characterize the spatial proteomics of the hallmarks of cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / chemistry
  • Fluorescent Antibody Technique / methods*
  • Fluorescent Dyes / chemistry
  • Humans
  • MCF-7 Cells
  • Mice
  • Mice, Nude
  • Neoplasms, Experimental / diagnostic imaging*
  • Neoplasms, Experimental / metabolism
  • Oligonucleotides / chemistry

Substances

  • Antibodies
  • Fluorescent Dyes
  • Oligonucleotides